The metabolic reprogramming of T cells controls airway remodeling in severe asthma

Read full text Summarise with VIRAT
Authors: Hope Steele, Elizabeth Kato, Garrison Dell, Maeve Fink, Andrew Ghastine, Ashley Willicut, Hilde Cheroutre, Mitchell Kronenberg, Rana Herro
Cited by: 0
References: 82

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Mixed granulocytic asthma (MGA) is a severe Th2-low endotype, characterized by high Th17/neutrophilic burden and exacerbated airway remodeling.Both features confer resistance to inhaled corticosteroids and typical asthma treatments.Objective: We aimed to address gaps in knowledge, including how Th17 cells induce pathological tissue remodeling and how Th17 differentiation occurs in response to allergens. Methods:We generated a Th2-low murine model of asthma on the Il4rα -/-background that mimics the decrease in type 2 response seen in corticosteroid-resistant patients.We monitored major features of human disease including heightened airway reactivity to methacholine, Th17/neutrophilic inflammation, airway remodeling, and resistance to corticosteroid treatment.Comparative transfer of Th2 versus Th17 cells were analyzed.We further investigated how the mitochondrial oxidative phosphorylation (OXPHOS) pathway modulates pathogenic Th17 cell reprogramming by in vitro T cell cultures and in vivo therapeutic blockades.Results: LIGHT (aka TNFSF14) and the OXPHOS pathway are enriched in human MGA and likewise upregulated in this mouse model.We show OXPHOS promotes the metabolic reprograming of Th17 cells, to sustain their survival despite steroid treatment and produce LIGHT that controls airway remodeling.Mechanistically, OXPHOS regulates RORγt expression and the subsequent transcriptional network to program differentiation of Th17 cells, whereas LIGHT drives airway remodeling by activating the MMP9-dependent TGFβ pathway.Additionally, OXPHOS + Th17 cells promote the expression of osteopontin necessary for fibroblast activation.LIGHT antagonistic blockade reduces airway remodeling, whereas OXPHOS inhibition kills Th17 cells and subsequent neutrophilia.Importantly, the dual blockade of LIGHT and OXPHOS reverses all features of MGA back to baseline and reciprocally increases the numbers of Treg cells.Conclusions: The dual blockade of LIGHT and OXPHOS constitutes a promising target for clinical interventions in human MGA, possibly extending to other Th17-driven fibrotic diseases. J o u r n a l P r e -p r o o fKey Messages:• OXPHOS regulates RORγt expression and programming of pathogenic Th17 cells that are resistant to apoptosis.• Th17-derived LIGHT promotes airway remodeling by regulating MMP9-activation of TGF, and its inhibition reverses disease.• LIGHT and OXPHOS concomitant blockade, post-disease onset, abolishes central features of severe asthma including Th17/neutrophilic burden, airway remodeling, and airway hyperreactivity to methacholine. Capsule summary:OXPHOS-programmed Th17 cells produce LIGHT to control pathological remodeling.The combinatorial blockade of LIGHT/OXPHOS offers a novel therapeutic strategy to treat Th17driven fibrotic diseases, including severe asthma. J o u r n a l P r e -p r o o f

Fields of Study & Subjects

Asthma and respiratory diseases T-cell and B-cell Immunology Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
Journal of Allergy and Clinical Immunology
Publication date
1 November 2026
Language
EN